Litigation

In re Thalomid and Revlimid Antitrust Litigation

active

2:14-cv-06997

Patents at issue (1)

Summary

Antitrust litigation by purchaser/insurer classes against Celgene/BMS, in which the '106 patent is directly referenced as part of Celgene's Revlimid patent portfolio/alleged monopolization scheme. The case remains ongoing with appeals and summary-judgment briefing in 2024 (see Dkt. 446, 2:19-cv-07532).

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).